2020年4月18日,美国FDA宣布加速批准FGFR2抑制剂Pemigatinib的上市,用于治疗FGFR2基因融合或其它重排类型的经治晚期胆管癌患者。这一靶向药开启了胆管癌靶向治疗的大门,实现了胆管癌靶向治疗史上从无到有的突破,为胆管癌患者带来了新的希望。 一、胆管癌治疗的瓶颈 二、Pemigatinib的问世 三、双喜临门 温馨提示:如果您想与互助君或更多觅友交流,可添加肝癌互助君微信mijian004。 推荐阅读: [1]Gupta A,Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma[J].Hepatobiliary Surg Nutr,2017,6 ( 2 ) : 101-104 [2]Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280. doi:10.1038/nrgastro.2016.51 [3]Spolverato G,Kim Y,Alexandrescu S,et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J].Ann Surg Oncol,2016,23( 1) : 235-243. [4]Si A,Li J,Xing X,et al. Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes[J].Surgery,2017,161( 4) : 897-908. [5]胆管癌诊断与治疗——外科专家共识[J].中国实用外科杂志,2014(1):1-5. [6]Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [published online ahead of print, 2020 Mar 20]. Lancet Oncol. 2020;S1470-2045(20)30doi:10.1016/S1470-2045(20)30109-1109-1. [7]https://www./news-events/press-announcements/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts.
|
|